Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Time to viral- 20% Improvement Relative Risk c19early.org/pl Shao et al. Paxlovid for COVID-19 EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Retrospective 131 patients in China (April - May 2022) Study compares with lianhuaqingwen, results vs. placebo may differ Faster viral clearance with paxlovid (p=0.00056) Shao et al., medRxiv, doi:10.1101/2022.07.03.22277169 Favors paxlovid Favors lianhuaqingwen
Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China
Shao et al., medRxiv, doi:10.1101/2022.07.03.22277169 (Preprint)
Shao et al., Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China, medRxiv, doi:10.1101/2022.07.03.22277169 (Preprint)
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 17 paxlovid and 114 lianhuaqingwen patients in China, showing faster viral clearance with paxlovid.
[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
time to viral-, 20.0% lower, relative time 0.80, p < 0.001, treatment 17, control 114.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shao et al., 6 Jul 2022, retrospective, China, preprint, median age 52.0, 12 authors, study period 6 April, 2022 - 11 May, 2022, this trial compares with another treatment - results may be better when compared to placebo.
Contact: huanggang@sumhs.edu.cn, hujianrong@jdhospital.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.03.22277169; this version posted July 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Title: Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China Jiasheng Shao 1*, Rong Fan 2*, Tiejun Zhang3*, Catherine Lee4, Xuyuan Huang5, Fei Wang6, Haiying Liang7, Ye Jin7, Ying Jiang7, Yanhua Gu8, Jianrong Hu7#, Gang Huang9# 、 Department of Infectious Diseases and Immunology, Jiading District Central 1 Hospital, Shanghai University of Medicine and Health Sciences, Shanghai 201899, China 、 Genomics, Center for Molecular and Cellular Bioengineering, Biotechnology 2 Center, Technische Universität Dresden 01307, Germany 、 Department of Epidemiology, School of Public Health, Fudan University, 3 Shanghai 200032, China 、 College of Public Health, University of Georgia, Athens, GA 30602, USA 5、 Department of Urology, Renji Hospital, Shanghai Jiaotong University, 4 Shanghai 200127, China 、 Department of Intensive Care Unit, Jiading District Central Hospital, Shanghai 6 201899, China 、 Department of Respiratory Medicine, Jiading District Central Hospital, 7 Shanghai 201899, China 、 Department of Nursing, Jiading District Central Hospital, Shanghai 201899, 8 China 、 Shanghai Key Laboratory of Molecular Imaging, Shanghai University of 9 Medicine and Health Sciences, Shanghai 201318, China 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.07.03.22277169; this version posted July 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Running title: Omicron variant clinical advancement in Shanghai # Corresponding Authors: Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China, E-mail address: huanggang@sumhs.edu.cn (G. Huang), Tel: 86-021-65881330 Department of Respiratory Medicine, Jiading District Central Hospital, Shanghai 201899, China E-mail address: hujianrong@jdhospital.com (J. Hu), Tel: 86-021-67073583 *These authors contributed equally to this work. Keyword: SARS-CoV-2; Omicron variant; Vaccination; PCR conversion; Paxlovid ABSTRACT Background Studies on the Omicron variant infection have generally been restricted to descriptions of its initial clinical and epidemiological characteristics. We investigated the timeline-related advancement in individuals with Omicron variant. Methods We conducted a retrospective, single-centered study including 226 laboratory-confirmed cases with Omicron variant between April 6th and May 11th, 2022 in Shanghai, China. Final date of follow-up was May 30, 2022. Results Among 226 enrolled patients, the median age was 52 years old, and 118 (52.2%) were female. The duration from onset of symptoms to hospitalization was 3 days (interquartile range [IQR]: 2-4 days) for symptomatic patients. Cough occurred in 2 medRxiv preprint doi: https://doi.org/10.1101/2022.07.03.22277169; this version posted July 6, 2022. The copyright holder..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit